+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Multi-ethnic differences in breast cancer: current concepts and future directions

Multi-ethnic differences in breast cancer: current concepts and future directions

International Journal of Cancer 106(4): 463-467

Granulomas are characterized histologically by a nodular collection of macrophages with occasional admixture of epithelioid cells, multinucleate giant cells, and other immunocompetent cells. Chemokines are considered to play an important role in the recruitment of these constituent cells of granulomas. The present study has examined the effect of a deficiency of C-C chemokine receptor-2 (CCR2) on hepatic granuloma formation induced by a single injection of Zymosan A. In CCR2+/+ mice, the number and the size of granulomas gradually increased until they reached peak values at 10 days after the injection. In contrast, both the number and the size of granulomas were smaller in CCR2-/- mice than in CCR2+/+ mice from days 5 to 21. They showed low peaks at day 5, after which the number and the size of the granulomas gradually decreased. Immunohistochemical analysis of the constituent granuloma cells using cell type-specific monoclonal antibodies revealed rapid accumulation of blood monocytes, with subsequent differentiation to macrophages, in CCR2+/+ mice during days 2-10. This process was greatly impaired in CCR2-/- mice and granulomas remained small. At all time points, the percentage of polymorphonuclear cells in granulomas was higher in CCR2-/- mice than in CCR2+/+ mice. Interestingly, multinucleate giant cells were frequently observed in granulomas in CCR2-/- mice, whereas they rarely appeared in CCR2+/+ mice. Profiles of liver cytokine RNA levels as well as serum cytokine levels revealed reduced expression of the Th1 cytokine IFN-gamma in CCR2-/- mice. These data clearly indicate that signalling through CCR2 has many effects on the normal growth and development of hepatic granulomas.

(PDF emailed within 0-6 h: $19.90)

Accession: 035349173

Download citation: RISBibTeXText

PMID: 12845638

DOI: 10.1002/ijc.11237

Related references

Current concepts and future directions in neoadjuvant chemotherapy of breast cancer. Memo 11(3): 199-203, 2018

Ductal carcinoma in situ of the breast: current concepts and future directions. Archives of Pathology and Laboratory Medicine 137(4): 462-466, 2013

Current concepts and future directions in differentiated thyroid cancer. Clinical Biochemist. Reviews 31(1): 9-19, 2010

Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. Journal of Thoracic Oncology 9(11): 1609-1617, 2015

Personalized treatment of early-stage breast cancer: present concepts and future directions. Cancer Treatment Reviews 36(8): 584-594, 2010

Genetic counseling for breast cancer risk: general concepts, challenging themes and future directions. Breast Disease 27: 69-96, 2007

Chemotherapy with Platinum Compounds: Current Status and Future Directions. Volume 3: Dosing, Head and Neck Cancer, Genitourinary Cancer, Pediatric Cancer, Tumor of Unknown Origin, Dose Intensity, Future Directions. Kona, Hawaii, February 24-28, 1993. Seminars in Oncology 21(5 Suppl 12): 1-118, 1994

Early breast cancer--an overview of current and future directions. Australasian Radiology 31(2): 113-118, 1987

Docetaxel in breast cancer Current status and future directions. Cancer Investigation 17(SUPPL 1): 45-46, 1999

Pharmacogenomics in breast cancer: current trends and future directions. Current Opinion in Molecular Therapeutics 6(3): 296-301, 2004

Epothilones in breast cancer: current status and future directions. Expert Review of Anticancer Therapy 8(8): 1299-1311, 2008

Current Practice and Future Directions for Metaplastic Breast Cancer. Annals of Surgical Oncology 2018, 2018

Exemestane in breast cancer: current status and future directions. Clinical Breast Cancer 1 Suppl 1: S28-S33, 2002

Current status and future directions in breast cancer therapy. Clinical Breast Cancer 4 Suppl 2: S70-S75, 2003

Breast Cancer Chemoprevention Current Approachesand Future Directions. Current Obstetrics and Gynecology Reports 1(1): 33-41, 2012